BRIACELL THERAPEUTICS CORP. Increase (Decrease) in Prepaid Expense
BRIACELL THERAPEUTICS CORP. (BCTX) reported Increase (Decrease) in Prepaid Expense of -$492.28 thousand for the 12-month period ending 2025-07-31, per its 10-K filed 2025-10-16.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInPrepaidExpense · last filed 2025-10-16
- BRIACELL THERAPEUTICS CORP. increase (decrease) in prepaid expense for the quarter ending 2025-07-31 was -$758.57K.
- BRIACELL THERAPEUTICS CORP. increase (decrease) in prepaid expense for the quarter ending 2025-04-30 was $185.97K.
- BRIACELL THERAPEUTICS CORP. increase (decrease) in prepaid expense for the quarter ending 2025-01-31 was -$291.53K, a 128.40% decline year-over-year.
- BRIACELL THERAPEUTICS CORP. increase (decrease) in prepaid expense for the quarter ending 2024-10-31 was $371.85K.
- BRIACELL THERAPEUTICS CORP. increase (decrease) in prepaid expense for fiscal 2025 was -$492.28K.
- BRIACELL THERAPEUTICS CORP. increase (decrease) in prepaid expense for fiscal 2024 was -$2.13M, a 148.35% decline from fiscal 2023.
- BRIACELL THERAPEUTICS CORP. increase (decrease) in prepaid expense for fiscal 2023 was $4.40M, a 475.56% increase from fiscal 2022.
- BRIACELL THERAPEUTICS CORP. increase (decrease) in prepaid expense for fiscal 2022 was $764.05K, a 656.61% increase from fiscal 2021.
| Period end | Increase (Decrease) in Prepaid Expense 3 month | Increase (Decrease) in Prepaid Expense 6 month | Increase (Decrease) in Prepaid Expense 9 month | Increase (Decrease) in Prepaid Expense 12 month |
|---|---|---|---|---|
| 2025-07-31 | -$758.57K derived: 10-K 12 month − 10-Q 9 month · filed 2025-10-16 | -$572.61K derived: sum of 2 quarters · filed 2025-10-16 | -$864.13K derived: sum of 3 quarters · filed 2025-10-16 | -$492.28K 10-K · filed 2025-10-16 |
| 2025-04-30 | $185.97K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-06-16 | -$105.56K derived: sum of 2 quarters · filed 2025-06-16 | $266.30K 10-Q · filed 2025-06-16 | -$1.06M derived: sum of 4 quarters · filed 2025-10-16 |
| 2025-01-31 | -$291.53K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-03-12 | $80.33K 10-Q · filed 2025-03-12 | -$1.25M derived: sum of 3 quarters · filed 2025-10-16 | -$2.13M derived: sum of 4 quarters · filed 2025-10-16 |
| 2024-10-31 | $371.85K 10-Q · filed 2024-12-16 | -$954.95K derived: sum of 2 quarters · filed 2025-10-16 | -$1.84M derived: sum of 3 quarters · filed 2025-10-16 | -$816.61K derived: sum of 4 quarters · filed 2025-10-16 |
| 2024-07-31 | -$1.33M derived: 10-K 12 month − 10-Q 9 month · filed 2025-10-16 | -$2.22M derived: sum of 2 quarters · filed 2025-10-16 | -$1.19M derived: sum of 3 quarters · filed 2025-10-16 | -$2.13M 10-K · filed 2025-10-16 |
| 2024-04-30 | -$888.22K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-06-16 | $138.34K derived: sum of 2 quarters · filed 2025-06-16 | -$799.48K 10-Q · filed 2025-06-16 | $3.56M derived: sum of 4 quarters · filed 2025-06-16 |
| 2024-01-31 | $1.03M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-03-12 | $88.74K 10-Q · filed 2025-03-12 | $4.45M derived: sum of 3 quarters · filed 2025-03-12 | $5.34M derived: sum of 4 quarters · filed 2025-03-12 |
| 2023-10-31 | -$937.82K 10-Q · filed 2024-12-16 | $3.42M derived: sum of 2 quarters · filed 2024-12-16 | $4.31M derived: sum of 3 quarters · filed 2024-12-16 | $4.00M derived: sum of 4 quarters · filed 2024-12-16 |
| 2023-07-31 | $4.36M derived: 10-K 12 month − 10-Q 9 month · filed 2024-10-29 | $5.25M derived: sum of 2 quarters · filed 2024-10-29 | $4.94M derived: sum of 3 quarters · filed 2024-10-29 | $4.40M 10-K · filed 2024-10-29 |
| 2023-04-30 | $888.59K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-06-14 | $575.86K derived: sum of 2 quarters · filed 2024-06-14 | $37.04K 10-Q · filed 2024-06-14 | -$366.90K derived: sum of 4 quarters · filed 2024-06-14 |
| 2023-01-31 | -$312.73K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-03-18 | -$851.55K 10-Q · filed 2024-03-18 | -$1.26M derived: sum of 3 quarters · filed 2024-03-18 | $122.53K derived: sum of 4 quarters · filed 2024-03-18 |
| 2022-10-31 | -$538.82K 10-Q · filed 2023-12-14 | -$942.76K derived: sum of 2 quarters · filed 2023-12-14 | $435.25K derived: sum of 3 quarters · filed 2023-12-14 | $335.34K derived: sum of 4 quarters · filed 2023-12-14 |
| 2022-07-31 | -$403.94K derived: 10-K 12 month − 10-Q 9 month · filed 2023-10-25 | $974.08K derived: sum of 2 quarters · filed 2023-10-25 | $874.16K derived: sum of 3 quarters · filed 2023-10-25 | $764.05K 10-K · filed 2023-10-25 |
| 2022-04-30 | $1.38M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-06-14 | $1.28M derived: sum of 2 quarters · filed 2023-06-14 | $1.17M 10-Q · filed 2023-06-14 | |
| 2022-01-31 | -$99.92K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-03-16 | -$210.02K 10-Q · filed 2023-03-16 | ||
| 2021-10-31 | -$110.11K 10-Q · filed 2022-12-14 | |||
| 2021-07-31 | $100.98K 10-K · filed 2022-10-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |